Equity Bancshares (NYSE: EQBK) clears regulatory non-objection for 1,000,000-share buyback
Rhea-AI Filing Summary
Equity Bancshares, Inc. approved a share repurchase plan for up to 1,000,000 shares of its outstanding common stock. The one-year repurchase period will begin on the earlier of completion of purchases under the October 1, 2025 to September 30, 2026 authorization or that authorization’s September 30, 2026 expiration.
The program does not obligate the company to repurchase a specific dollar amount or number of shares and may be extended, modified, or discontinued at any time without notice. The Federal Reserve Bank of Kansas City issued a non-objection to this repurchase plan on August 5, 2026.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
Repurchase authorization size: 1,000,000 shares
Board approval date: May 20, 2026
Regulatory non-objection date: August 5, 2026
+3 more
6 metrics
Repurchase authorization size
1,000,000 shares
Maximum number of outstanding common shares authorized for repurchase under the new plan
Board approval date
May 20, 2026
Date the Board of Directors approved the share repurchase plan
Regulatory non-objection date
August 5, 2026
Date the Federal Reserve Bank of Kansas City issued non-objection to the plan
Current authorization period start
October 1, 2025
Start date of the existing repurchase authorization referenced by the new plan
Current authorization expiration
September 30, 2026
Expiration date of the existing authorization that gates the start of the new plan’s one-year term
New plan duration
one-year period
Length of time during which up to 1,000,000 shares may be repurchased after the plan begins
Key Terms
share repurchase plan, non-objection, authorization, Emerging growth company
4 terms
non-objection regulatory
"Non-objection from the Federal Reserve Bank of Kansas City related to this repurchase plan"
A non-objection is an official indication from a regulator or authority that it does not oppose a proposed action, such as a transaction, filing, or study; it is not the same as a full approval but is a practical green light to proceed. For investors, a non-objection lowers regulatory uncertainty and makes a planned deal or project more likely to move forward, though conditions or further review can still apply — think of it as a neighbor who doesn’t object to your fence, letting you build while not endorsing it fully.
authorization financial
"completion of purchases under the October 1, 2025 to September 30, 2026 authorization"
Authorization is a formal permission granted by an authority—such as a regulator, board of directors, or government—to carry out a specific activity, sell a product, or use funds. For investors, authorization matters because it often unlocks a company’s ability to generate revenue, launch products, or execute transactions; think of it like a license or green light that reduces uncertainty and can materially change a company’s prospects.
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
AI-generated analysis. How Rhea-AI works. Not financial advice.
